Literature DB >> 34320282

Revisiting FDA Approval of Aducanumab.

G Caleb Alexander1, David S Knopman1, Scott S Emerson1, Bruce Ovbiagele1, Richard J Kryscio1, Joel S Perlmutter1, Aaron S Kesselheim1.   

Abstract

Entities:  

Year:  2021        PMID： 34320282     DOI： 10.1056/NEJMp2110468

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  28 in total

1.  Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia.

Authors:  Gege Gui; Christopher S Hourigan
Journal:  Cancer J       Date:  2022 Jan-Feb 01       Impact factor: 3.360

2.  All you need is love: Yet another social determinant of health.

Authors:  Diane E Meier; R Sean Morrison
Journal:  J Am Geriatr Soc       Date:  2021-09-12       Impact factor: 5.562

3.  Transplantation of Nasal Olfactory Mucosa Mesenchymal Stem Cells Benefits Alzheimer's Disease.

Authors:  Chun-Gu Hong; Meng-Lu Chen; Ran Duan; Ming Lu; Hui Xie; Zheng-Zhao Liu; Xin Wang; Zhi-Lin Pang; Li-Te Ge
Journal:  Mol Neurobiol       Date:  2022-09-29       Impact factor: 5.682

4.  Expedited regulatory product approval in the time of COVID-19.

Authors:  Gary D Novack
Journal:  Ocul Surf       Date:  2022-05-28       Impact factor: 6.268

5.  A Proposal to Increase Value and Equity in the Development and Distribution of New Pharmaceuticals.

Authors:  Paul Sorum; Christopher Stein; Danielle Wales; David Pratt
Journal:  Int J Health Serv       Date:  2022-05-12       Impact factor: 1.851

6.  Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

Authors:  Eric L Ross; Marc S Weinberg; Steven E Arnold
Journal:  JAMA Neurol       Date:  2022-05-01       Impact factor: 29.907

7.  Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.

Authors:  Gregory S Day; Nikolaos Scarmeas; Richard Dubinsky; Katherine Coerver; Anitra Mostacero; Brooks West; Scott R Wessels; Melissa J Armstrong
Journal:  Neurology       Date:  2022-02-23       Impact factor: 11.800

Review 8.  The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics.

Authors:  Eric Karran; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2022-02-17       Impact factor: 112.288

9.  Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.

Authors:  Eleonora Lacorte; Antonio Ancidoni; Valerio Zaccaria; Giulia Remoli; Leonardo Tariciotti; Guido Bellomo; Francesco Sciancalepore; Massimo Corbo; Flavia L Lombardo; Ilaria Bacigalupo; Marco Canevelli; Paola Piscopo; Nicola Vanacore
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.160

10.  Chemical-Driven Outflow of Dissociated Amyloid Burden from Brain to Blood.

Authors:  Donghee Lee; Hyunjin Vincent Kim; Hye Yun Kim; YoungSoo Kim
Journal:  Adv Sci (Weinh)       Date:  2022-02-02       Impact factor: 17.521
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.